The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Jan 21 (Reuters) - Merck and the Coalition for Epidemic Preparedness Innovations said on Wednesday they have partnered on a ...

Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...

Merck & Co., Inc. (NYSE:MRK) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported that Merck & Co., ...

Jan 20 () - Moderna ​and Merck ‌said on ‌Tuesday their experimental vaccine for ⁠a ‌serious type of ‍skin cancer, used in ...

Guardant Health is signing up to a multiyear deal with Merck & Co. for the U.S. Big Pharma to tap its Infinity Smart platform ...

The company’s previous CCO was Cristal Downing, who joined Insulet as chief corporate affairs officer late last year.

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in what would be the latest big deal in the red-hot ...

Jan 25 (Reuters) - Merck is no longer in discussions to buy cancer drug developer Revolution Medicines, the Wall Street ...